

AI-based benchmark to test the potential of 3-photon excited fluorescence in intraoperative lung cancer detection with multiphoton microscopy

Siem de Jong¹, Annick J. H. E. van der Kroef², Marie Louise Groot³, Roel L. J. Verhoeven², Erik H. F. M. van der Heijden², Francesco Ciompi¹

¹Radboud university medical center, Department of Pathology, Nijmegen, The Netherlands,

²Radboud university medical center, Department of Pulmonary Diseases, Nijmegen, The Netherlands,

³LaserLab Amsterdam, Department of Physics, Faculty of Science, VU Amsterdam, Amsterdam, The Netherlands


Graphical Abstract

Suspected lung cancer patients (n=179) underwent bronchoscopy and biopsies (235) were included

Acquired rapid on-site HHGM images of biopsies

Developed AI pipeline to detect lung cancer in HHGM images

Used AI pipeline to test model hypotheses
(e.g. "does 3-photon excited fluorescence, 3PEF, improve cancer detection performance?")



Abstract

Introduction: Higher harmonic generation microscopy (HHGM) enables intra-operative tissue analysis of lung biopsies, producing images for automated analysis^{1,2}. Our microscope includes detection channels for 2- and 3-photon excited fluorescence (3PEF) enabling imaging of flavin adenine dinucleotide (FAD) and nicotinamide adenine dinucleotide (NADH) showing metabolic activity. The autofluorescence lifetimes of FAD and NADH decrease in cancer³.

Aims and objectives: This study aims to establish an AI-based benchmark to evaluate HHGM components in lung cancer detection, demonstrating the benefit of 3PEF.


Methods: HHGM images from 235 navigation bronchoscopy biopsies from 179 patients, were collected. To detect tumor, a neural network was trained with self-supervision to extract domain-specific features before training a binary tumor classifier. The performance was evaluated using 8-fold cross-validation and the area under the receiver operating characteristic curve with equivalence tested via the Wilcoxon signed-rank test.

Results: An AI-based benchmark was built to test lung cancer detection with HHGM hypotheses. Preliminary experiments show that including 3PEF did not alter model outcomes ($p=0.74$).


Conclusions: While further validation is needed regarding 3PEF's added value for tumor detection, we introduced an AI-based validation framework extensible to other tumor detection hypotheses and endpoints including segmentation and prognosis.

We developed an adaptable AI framework to detect lung cancer in bronchoscopy biopsies with label-free microscopy. Experiments on our data show comparable performance with and without 3-photon excited fluorescence.


1 Higher harmonic generation microscopy (HHGM) images cells and interfaces, collagen, elastin and cellular fluorophores, and flavin adenine dinucleotide (FAD), nicotinamide adenine dinucleotide (NADH)⁴. The portable microscope can be transported to the operating room.




3 The 2-stage AI framework consists of extracting features and detecting cancer. Heatmaps provide interpretability.



2 HHGM has the potential to improve rapid on-site evaluation (ROSE)⁵ through label-free histology imaging and the capability for on-site AI-assisted analysis.



4 We trained models with and without 3PEF on 235 biopsies using 8-fold cross-validation and measured area under the receiver operating characteristic curve (AUROC) and found no difference ($p=0.74$)



¹L. M. G. van Huizen, M. Blokker, J. M. A. Daniels, T. Radonic, J. H. Von Der Thüsen, M. Veta, J. T. Annema, M. L. Groot, *Mod. Pathol.* 38(1), 100633 (2025).

²S. de Jong, M. L. Groot, R. L. J. Verhoeven, E. H. F. M. van der Heijden, F. Ciompi, In *Medical Imaging with Deep Learning* (2024).

³M. Wang, F. Tang, X. Pan, L. Yao, X. Wang, Y. Jing, J. Ma, G. Wang, L. Mi, *BBA Clinical*, 8, 7–13 (2017).

⁴L. M. G. van Huizen, T. Radonic, F. van Mourik, D. Seinstra, C. Dickhoff, J. M. A. Daniels, I. Bahce, J. T. Annema, M. L. Groot, *Transl Biophotonics*, 2(4), e20200009 (2020).

⁵E. P. Kops, L. J. W. van der Burgt, S. Vos, L. J. M. van Zuijlen-Manders, R. L. J. Verhoeven, E. H. F. M. van der Heijden, *Cancer cytopathol.*, 132(4), 233–241, (2024).

⁶M. Oquab, T. Daract, T. Moutakanni, H. Vo, M. Szafraniec, V. Khalidov, P. Fernandez, D. Haziza, F. Massa, A. El-Nouby, ..., P. Bojanowski, *arXiv:2304.07193 [cs.CV]* (2023).

⁷M. Y. Lu, D. F. K. Williamson, T. Y. Chen, R. J. Chen, M. Barbieri, F. Mahmood, *Nat Biomed Eng* 5, 555–570 (2021).

This study was funded by the European Union under the IMAGIO grant number 101112053.